Fzata, Inc. Announces New Board Member
On May 16, 2025, Fzata, Inc., a biotechnology company specializing in innovative oral biologics, has made a significant announcement regarding its leadership. The company has appointed Gianna Arnold, JD, MS, as an independent member of its board of directors. With a robust background in corporate law and the biopharma sector, Arnold is set to enhance Fzata's strategic direction.
Gianna Arnold's Professional Background
Gianna Arnold comes to Fzata with over three decades of experience within the legal and biopharmaceutical domains. She serves as counsel with Saul Ewing, LLP and holds the CEO position at NuMoon Technologies, LLC. Her expertise primarily lies in corporate transactions, especially in negotiating strategic alliances and conducting meticulous due diligence for mergers, acquisitions, and licensing arrangements.
Dr. Zhiyong Yang, Fzata's Chairman and CEO, expressed enthusiasm about Arnold's appointment. "Gianna has been an invaluable member of our business advisory committee. Her deep understanding of the transactional landscape will be crucial as we seek strategic partnerships in the pharmaceutical industry and prepare for our upcoming equity financing phase."
Contributions to the Life Sciences Sector
Arnold's accolades further attest to her expertise. She has been recognized as one of America’s Best Lawyers for Biotechnology and Life Sciences, earning her spot on the prestigious list from 2016 through 2023. Additionally, she has been included in Chambers USA's "America's Leading Lawyers in Intellectual Property" list, reflecting her prominent role in the field.
Insights from Gianna Arnold
Expressing her excitement regarding the new role, Arnold said, "I am thrilled to join Fzata and contribute my insights on corporate transactions. I have worked closely with the CEO on strategic initiatives since Fzata's spinout from the University of Maryland Baltimore. I am continually impressed by Fzata's growth trajectory and the potential of its oral biologics platform to revolutionize patient care."
About Fzata, Inc.
Fzata has pioneered a next-generation oral biologics technology known as Bioengineered Probiotic Yeast Medicines (BioPYM™). This innovative approach utilizes live yeast as a delivery tool for therapeutic biologics, effectively creating a micro-factory within the gastrointestinal system to directly produce necessary medicines. Fzata has developed a comprehensive pipeline of yeast-based drug candidates aimed at treating gastrointestinal ailments and enhancing gut health.
For more detailed information about Fzata and its groundbreaking work in biopharmaceuticals, you can visit
Fzata's official website or follow them on LinkedIn at
Fzata's LinkedIn Page.
Overall, the addition of Gianna Arnold to the board not only marks a significant milestone in Fzata’s leadership but also promises a strengthened strategic direction as the company continues to innovate in the biopharma space.